July 28, 2006

To whom it may concern,

NK4 Patented in Japan as an Antitumor Agent to Inhibit Tumor Invasion and Metastasis

July 28, 2006—Kringle Pharma, Inc., a pharmaceutical company based in Toyonaka, Osaka and headed by President Kunio Iwatani announces that NK4 has been patented in Japan as an antitumor agent to inhibit tumor invasion and metastasis and that the patent (patent number 3832674) was published in the Japanese Patent Gazette.

NK4 is an internal fragment, generated by the elastase treatment of hepatocyte growth factor (HGF), that acts as a competitive antagonist for HGF to effectively inhibit tumor invasion and metastasis. This breakthrough is related to cancer treatments using NK4 and provides a basis for the development of NK4 as an antitumor agent.

NK4 has already been patented in Europe (December 2004, EP0890361) and the U.S. (February 2005, US Pat. No. 6,855,685). Kringle Pharma has obtained an exclusive license for these patents from Professor Toshikazu Nakamura at the Graduate School of Medicine, Osaka University, who initially made the discovery.

Encouraged by the issuing of the patent in Japan, Kunio Iwatani said, “Now that NK4 has finally been patented in Japan following Europe and the United States, a foundation has been established upon which NK4 pharmaceutical development projects can proceed in Japan, the U.S. and Europe. We will further accelerate these projects with the aim of forming an alliance with leading pharmaceutical companies.”

Kringle Pharma has also obtained exclusive licenses for other pending patents on NK4 for its effectiveness against diseases involving excessive angiogenesis. Kringle Pharma will work toward expanding NK4’s scope of application while making further efforts to enhance intellectual property.

For more information, contact
Mami Machide
Manager, Intellectual Property
info@kringle-pharma.com